Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Visual benefit versus visual gain: What is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ocular adnexal lymphoma in Denmark: a nationwide study of 387 cases from 1980 to 2017

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Fungal infection after endothelial keratoplasty: Association with hypothermic corneal storage

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Retinal layer segmentation in rodent OCT images: Local intensity profiles & fully convolutional neural networks

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Progression Over 5 Years of Prelaminar Hyperreflective Lines to Optic Disc Drusen in the Copenhagen Child Cohort 2000 Eye Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Migration of an outer retinal element in a healthy child followed by longitudinal multimodal imaging

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background: This study aimed to elucidate visual benefits of ranibizumab in patients with neovascular age-related macular degeneration (nAMD) compared with control arms and identify factors affecting response. Methods: This is a post-hoc pooled analysis of two phase III studies, ANCHOR and MARINA, of ranibizumab for the treatment of nAMD. ANCHOR included 83 international sites. MARINA included 96 sites in the USA. Analysis included patients (control, n=323; ranibizumab, n=332) with nAMD and a baseline best-corrected visual acuity (BCVA) of ≥35-<85 letters. Results: Patients receiving ranibizumab achieved an adjusted mean BCVA superiority of 18.9 and 21.2 letters over 12 and 24 months, respectively, compared with control. Ranibizumab treatment, higher baseline BCVA, lower age and smaller lesion size were positively associated with the ability to achieve BCVA >69 letters. Patients with the highest baseline BCVA had lowest BCVA gains. Ranibizumab treatment, lower baseline BCVA, lower age and smaller lesion size were identified as significant predictors of BCVA gain from baseline at month 24 (all p<0.0001). However, the difference in mean BCVA gains at month 24 between treatment and control groups was similar for all baseline BCVA subgroups (≥35-<55 letters, 21.9 letters; ≥55-<70 letters, 25.2 letters; ≥70-<85 letters, 19.3 letters). Conclusions: Higher baseline BCVA is associated with lower BCVA gains but a greater likelihood of achieving good final BCVA >69 letters due to smaller gains needed to achieve response. Visual benefits, including maintenance of visual acuity (VA), final VA achieved and relative gain compared with natural disease progression, should be considered when assessing treatment response in nAMD.

OriginalsprogEngelsk
TidsskriftBritish Journal of Ophthalmology
Vol/bind104
Udgave nummer5
Sider (fra-til)672-677
Antal sider6
ISSN0007-1161
DOI
StatusUdgivet - maj 2020

ID: 59452306